Bolag
Scandinavian Real Heart är verksamt inom medicinteknik. Bolaget bedriver forskning och utveckling inom observationer av hjärtats fysiologi. Utvecklingen av bolagets produkt, ett komplett artificiellt hjärta, sker i samarbete med hjärtkirurger, forskare och ingenjörer. Fokus ligger på att utveckla patenterade lösningar som kan imitera det naturliga mänskliga hjärtats blodcirkulation, med mål att användas av patienter som diagnostiserats med hjärtsvikt. Bolaget grundades år 2007.
Västerås - Scandinavian Real Heart AB (publ) today announced that the Company's Board of Directors has adopted a new strategic goal: that the Company shall be ready for the first-in-human implantation of the Realheart® Total Artificial Heart in February 2028.
Scandinavian Real Heart AB (publ) announces that the company’s half-year report for the period January – June 2026 will be published on August 26, 2026, instead of August 28, 2026, as previously communicated in the company’s financial calendar.
Västerås, Sweden, June 16, 2026 - Scandinavian Real Heart AB (publ) today released the recording of the Annual General Meeting held at the Company’s new premises in Västerås on May 28, 2026.
Scandinavian Real Heart AB (”Bolaget”) har den 28 maj 2026 hållit årsstämma där i huvudsak följande beslut fattades.
On 28 May 2026, Scandinavian Real Heart AB (the "Company") held its Annual General Meeting (AGM) at which the following resolutions were adopted.
Västerås, Sweden, May 28, 2026 – Scandinavian Real Heart AB (publ) announces today that CEO Ina Laura Perkins will present the company’s current progress, and future plans for Realheart® TAH at the Annual General Meeting on Thursday, May 28, 2026. The meeting will be held at the company’s new premises on Hydrovägen in Västerås.
Västerås, Sweden, June 28, 2026 – Scandinavian Real Heart AB (publ) today announced that IP Australia, the Australian intellectual property rights agency, has granted Realheart a patent covering central aspects of the Realheart® TAH technology. The granted claims include the design and operation of the total artificial heart, as well as the integrated feedback mechanism that regulates the device's cardiac output. The patent remains in force in Australia until 2041.
Västerås, Sweden, June 28, 2026 – Scandinavian Real Heart AB (publ) announces today that the company has been granted a patent approval in China. The patent covers a control method and system configuration for artificial heart products, such as Realheart® TAH, featuring integrated feedback mechanisms for real-time regulation of cardiac output. The approval grants patent protection in China until March 2041.
Aktieägarna i Scandinavian Real Heart AB, org.nr. 556729–5588 (”Bolaget”), kallas härmed till årsstämma den 28 maj kl. 17.00 på Scandinavian Real Hearts huvudkontor, Hydrovägen 4, 721 36 Västerås. Inregistrering till stämman börjar kl. 16.30.
Västerås, Sweden, April 21, 2026 – Scandinavian Real Heart AB (publ) announces today that a new in vitro study, published in the peer-reviewed journal Artificial Organs, demonstrates that the Realheart® TAH causes approximately half the level of hemolysis – the mechanical destruction of red blood cells – compared with the only FDA-approved artificial heart device currently in wide clinical use. The differences across all primary endpoints were statistically significant (p < 0.05).
Västerås, Sweden, April 9, 2026 – Scandinavian Real Heart AB (publ) announces today that the company’s artificial heart technology, its founder and inventor Dr. Azad Najar, and long-standing clinical research collaborator Professor Göran Dellgren are featured in the new SVT documentary series Victorias Hjärta, premiering on April 9, 2026.
Västerås, 20 mars 2026. Idag publicerar Realheart årsredovisningen för 2025.